Hyperhomocysteinemia impairs regional blood flow: involvements of endothelial and neuronal nitric oxide

Pflugers Archiv European Journal of Physiology

Volumn 468, Issue 9, 2016, Pages 1517-1525

  Toda, Noboru ^a   Okamura, Tomio ^b  

^a Toyama Institute for Cardiovascular Pharmacology Research   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cerebral blood flow; Coronary blood flow; Hyperhomocysteinemia; Nitric oxide; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; HOMOCYSTEINE; NITRIC OXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE;

ALZHEIMER DISEASE; BLOOD FLOW; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CARDIOVASCULAR FUNCTION; CORONARY ARTERY BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIA; KIDNEY CIRCULATION; NITRERGIC NERVE CELL; NONHUMAN; PERFUSION; PRIORITY JOURNAL; REVIEW; ANIMAL; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CEREBROVASCULAR CIRCULATION; CORONARY CIRCULATION; HUMANS; HYPERHOMOCYSTEINEMIA; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84978786132     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-016-1849-y     Document Type: Review

References (92)

1. Abahji TN, Nill L, Ide N, Keller C, Hoffmawnn U, Weiss N (2007) Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Acta Med Res 38:411–416
2. Alam MM, Mohammad AA, Shuaib U, Wang C, Ghani U, Schwindt B, Todd KG, Shyaoib A (2009) Homocysteine reduces endothelial progenitor cells in stroke patients through apoptosis. J Cereb Blood Flow Metab 29:157–165
3. Austin SA, Santhanam AV, Katusic ZS (2010) Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 107:1498–1502
4. Austin SA, Santhanam AV, Hintonb DJ, Choi DS, Katusic ZS (2013) Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology. J Neurochem 127:691–700
5. Becker JS, Adler A, Schneeberger A, Huang H, Wang Z, Walsh E, Koller A, Hintze TH (2005) Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation 111:2112–2118
6. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bonses C, Newcombe RG, Lewis (1998) Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in human adults. Circulation 98:1848–1852
7. Betzen C, White R, Zehendner CM, Pietrowski E, Bender B, Luhmann HJ, Kuhlmann CR (2009) Oxidative stress upregulates the NMDA receptor on cerebrovascular endothelium. Free Radic Biol Med 47:1212–1220
8. Boger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38:126–136
9. Brattsström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A (1992) Hyperhomocysteinemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 22:214–221
10. Brickman AM, Guzman VA, Gonzalez-Castellon M, Razlighi Q, Gu Y, Narkhede A, Janicki S, Ichise M, Stern Y, Manly JJ, Schupf N, Marshall RS (2015) Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett 592:54–58
11. Cankurtaran M, Yesil Y, Kuyumcu ME, Oztet ZA, Yavuz BB, Halil M, Ulger Z, Cankurtaran ES, Arilogul S (2013) Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer’s disease. J Alzheimers Dis 33:1051–105
12. Cao L, Lou X, Zou Z, Mou N, Wu W, Huang X, Tan H (2013) Folic acid attenuates hyperhomocysteinemia-induced glomerular damage in rats. Microvasc Res 89:146–152
13. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, Wang JZ, Liu GP (2013) Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem 124:388–396
14. Chambers JC, Obeid OA, Kooner JS (1999) Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 19:22–292
15. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hopper J, Turner RM, Thompson SG, Kooner JS (2000) Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 355:523–527
16. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS (2000) Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 102:2479–2483
17. Chao C-L, Lee Y-T (2000) Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke 31:907–2911
18. Chen Z, Li CS, Zhang J, Pang BS, Xia CQ, Liu XF (2005) Relationship between endothelial dysfunction and serum homocysterine in patients with coronary leasions. Clin Med Sci J 20:63–66
19. Chien S-J, Lin I-C, Hsu CN, Lo MH, Tain YL (2015) Homocysteine and arginine-to-asymmetric dimethylarginine ratio associated with blood pressure abnormalities in children with early chronic kidney disease. Circ J 79:2031–2037
20. Chisari M, Merrlo S, Sortino MA, Solomone S (2010) Long- term incubation with b-amykloid peptides impairs endothelium-dependent vasodilatation in isolated rat basilar artery. Pharmacol Res 61:157–161
21. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS (2008) Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol 294:H1530–H1540
22. Dayal S, Arning E, Bottiglieri T, Böger RH, Sigmund CD, Faraci FM, Lentz SR (2004) Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 35:1957–196
23. Dayal S, Rodinov RN, Arning E, Bottiglieri T, Kimoto M, Murray DJ, Cooke JP, Faraci FM, Lentz SR (2008) Tissue-specific down-regulation of dimethylarginine dimethylaminohydrolase in hyperhomocystemia. Am J Physiuol 295:H816–H825
24. De Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LA, Van de Voorde J, Lameite NH, Mortier S, Kluijtmans LA, Van de Voorde J, Lameite NH (2004) Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 109:2331–2336
25. Distrutti E, Mencarelli A, Santucci L, Renga B, Orlandi S, Donini A, Shah V, Fiorucci S (2008) The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology 47:659–667
26. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, MoldovanNI YM, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J (2000) Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106:483–49
27. Elali A, Thériault P, Préfontaine P, Rivest S (2013) Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral β-amyloid brain entry and aggregation. Acta Neuropath Commun 1:75
28. Er H, Evereklioglu C, Cumurcu T, Türköz Y, Ozerol E, Sahin K, Doganay S (2002) Serum homocysteine levels is increased and correlated with endothelin-1 and nitric oxide in Bahçet’s disease. Br J Ophthalmol 86:653–657
29. Fischer PA, Dominguez GN, Cuniberti LA, Matinez V, Werba JP, Ramirez AJ, Masnatta LD (2003) Hyperhomocysteinemia induces renal emodynamic dysfunction: is nitric oxide involved? J Am Soc Nephrol 14:653–660
30. Fu WY, Dudman NP, Perry MA, Wang XL (2002) Homocysteine attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 161:169–176
31. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond) 288:373–376
32. Hasegawa T, Ichiba M, Matsumoto SE, Kasanuki K, Hatano T, Fujishiro H, Iseki E, Hattori N, Yamada T, Tabira T (2012) Urinary homocysteic acid levels correlate with mini-mental state examination scores in Alzheimer’s disease patients. J Alzheimers Dis 31:59–64
33. He L, Zeng H, Li F, Feng J, Liu S, Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G (2010) Homocysterine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol 299:E1061–1065
34. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenster MS (2001) Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med 11:536–542
35. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Mlyllkangas L, Erkinjuntti T, Mäkelä M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R (2013) Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 136:2707–2716
36. Huang CW, Chang WN, Huang SH, Lui CC, Chen NC, Chang YT, Lee CC, Chang CC, Chang AY (2013) Impact of homocysteine on cortical perfusion and cognitive decline in mild Alzheimer’s disease. Eur J Neurol 20:1191–1197
37. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, 27 collaborators (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313:1325–1335
38. Hwang SY, Siow YL, Au-Yeung KK, House J (2011) Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney. Am J Physiol 300:F189–F198
39. Imbard A, Benoist JF, Esse R, Gupta S, Lebon S, de Vriese AS, de Baulny HO, Kruger W, Sciff M, Blom HJ (2015) High homocysteine induces betaine depletion. Biosci Rep 35, eoo222. doi:10.1042/BSR20150094
40. Ketsawatsomkron P, Pelham CJ, Groh S, Keen L, Faraci FM, Sigmund CD (2010) Does peroxisome proliferator-activated receptor-γ (PPAR-γ) protect from hypertension directly through effects in the vasculature? J Biol Chem 285:9311–9316
41. Kietadisorn R, Kietselaer BL, Schmidt HHHW, Moens An L (2011) Role of tetrahydrobiopterin (BH4) in hyperhomocysteiemia-induced endothelial dysfunction: new indication for this orphan-drug? Am J Physiol 300, E1176
42. Kuznetsova E, Schliebs R (2013) β-Amyloid, cholinergic transmission and cerebrovascular system—a developmental study in a mouse model of Alzheimer’s disease. Curr Pharm Des 19:6749–6765
43. Lee BJ, Huang MC, Chung LJ, Cheng CH, Lin KL, Su KH, Juang YC (2004) Folic acid and vitamin B12 are more effective than B6 in lowering fasting plasma homocystein concentration in patients with coronary artery disease. Eur J Clin Nutr 58:481–487
44. Lee H, Kim HJ, Kim J, Chang N (2004) Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia. Brain Res 996:139–147
45. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, René Malinow M, Heistad DD (1996) Vascular dysfunction in monkey with diet-induced hyperhomocysteinemia. J Clin Invest 98:24–29
46. Li JG, Praticό D (2015) High levels of homocysteine results in cerebral amyloid angiopathy in mice. J Alzheimers Dis 43:29–35
47. Li JG, Chu J, Barrero C, Merali S, Praticό D (2014) Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol 75:851–863
48. Li N, Yi F-X, Rute E, Zang DX, Slocum GR, Zou A-P (2002) Effects of homocysteine on intracellular nitric oxide and superoxide levels in the renal arterial endothelium. Am J Physiol 283:H1237–1243
49. Magne J, Huneau J-F, Borderie D et al (2015) Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia. Amino Acids 47:1975–1982
50. Malinow MR (1990) Hyperhomocyst(e)inemia. A common and easy reversible risk factor for occlusive atherosclerosis. Circulation 81:2004–2006
51. Miners JS, Palmer JC, Tayler H, Palmer LE, Ashby E, Kehoe PG, Love S (2014) Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes Front Aging Neurosci 6:238. doi:10.3389/fnagi.2014.00238, eCollection 2014
52. Moens AL, Champion HC, Claeye MJ, Tavazzi B, Kaminski PM, Wolin MS, Borgonjon DJ, Van Nassauw L, Haile A, Zviman M, Bedja D, Wuyts FL, Elsaesser RS, Cos P, Gabrielson KL, Lazzarino G, Paolocci N, Timmermans JP, Vrints CJ, Kass DA (2008) High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 117:1810–1819
53. Munjal C, Givvimani S, Qipshidze N, Tyagi N, Falcone JC, Tyagi SC (2011) Mesenteric vascular remodeling in hyperhomocysteinemia. Mol Cell Biolchem 348:99–108
54. Norsidah KZ, Asmadi AY, Azizi A, Faizah O, Kamisah Y (2013) Palm tocotrienol-rich fraction reduced plasma homocysteine and heart oxidative stress in rats with a high-methionine diet. J Physiol Biochem 69:441–449
55. Nygårdo O, Nordrehaug EJ, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. NEng J Med 337:230–236
56. Popa-Wagner A, Buga AM, Popescu B, Muresanu D (2013) Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Traum (Viena) 122(1):S47–S54
57. Price JM, Hellermann A, Hellermann G, Sutton ET (2004) Aging enhances vascular dysfunction induced by the Alzheimer’s peptide β-amyloid. Neurol Res 26:305–311
58. Qipshidze N, Tyagi N, Sen U, Givvimani S, Metreveli N, Lominadze D, Tyagi SC (2010) Folic acid mitigates cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine- metabolizing enzymes postmyocardial infarction in mice. Am J Physiol 299:H1484–1493
59. Racz A, Veresh Z, Lotz G, Bagi Z, Koller A (2010) Ctclooxygenase-2 derived thromboxane A2 and reactive oxygen species mediates flow-induced constriction of venules in hyperhomocysteinemia. Atherosclerosis 208:43–49
60. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD (2004) PPARγ agonist ropsiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43:661–666
61. Sekula M, Janawa G, Stankiewicz E, Stepień E (2011) Endothelial microparticle formation in moderate concentrations of homocysteine and methionine in vitro. Cell Mol Biol Lett 16:69–78
62. Selley ML (2003) Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease. Neurobiol Aging 24:903–907
63. Sen U, Rodriguez WE, Tyagi N, Kumar M, Kundu S, Tyagi SC (2008) Ciglitazone, a PPARγ agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol 295:E1205–E1212
64. Shastry S, Moning L, Tyagi N, Steed M, Tyagi SC (2005) GABA receptors and nitric oxide ameliorate constrictive collagen remodeling in hyperhomocysteinemia. J Cell Physiol 205:422–427
65. 12 and Alzheimer’s disease: insights from meta-analysis. J Alzheimers Dis 46:777–790
66. Sigmund CD (2010) Endothelial vascular muscle PPARγ in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension 55:437–444
67. Stamler JS, Loscalzo J (1992) Endothelium-derived relaxing factor modulates atherothrombogenic effects of homocysteine. J Cardiovasc Pharmacol 20(Suppl 12):S202–S204
68. Stamler JS, Osborne JA, Jaraki O, Robbani LE, Mullins M, Singel D, Loscalzo J (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308–318
69. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Henneckens CH (1992) A prospective study of plasma homosyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877–881
70. Stühilinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104:2569–2575
71. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, Recchia FA, Hintze TH (2007) Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 115:255–262
72. Sydow K, Schwedhelm E, Arakawa N, Bode-Bögar SM, Tsikas D, Hornig B, FrörichJC BRH (2003) ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57:244–252
73. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A (2001) Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 38(Suppl 2):S11–S14
74. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, Cooke JP, Loscalzo J, Fishman AJ, Creager MA, Gewirtz H (2002) Homocysteine impairs coronary microvascular dilator function in humans. J Am Coll Cardiol 40:1051–1058
75. Toda N, Ayajiki K (2014) Okamura T (2014) Obesity-induced cerebral hypoperfusion derived from endothelial dysfunction: one of the risk factors for Alzheimer’s disease. Curr Alzheimer Res 11:733–744
76. Toda N, Okamura T (2012) Cerebral blood flow regulation by nitric oxide in Alzheimer’s disease. J Alzheimer Dis 32:569–578
77. Toda N, Okamura T (2015) Recent advances in research on nitrergic-nerve mediated vasodilatation. Pflügers Arch Eur J Physiol 467:1165–1178
78. Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, Devid-Dyfillo M (2004) Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36:1532–1541
79. Tsuda K, Nishio I (2004) Serum homocysteine and endothelial dysfunction in circulation disorders in women. Circulation 120, e37
80. Tyagi N, Kandel M, Munjal C, Qipshidze N, Vacek JC, Pushpakumar SB, Metreveli N, Tyagi SC (2011) Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid. J Orthop Res 29:1511–1516
81. Tyagi N, Sedoris KC, Steed M, Ovechkin V, Moshal KS, Tyagi SC (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol 289:H2649–H2656
82. Ungvari Z, Zsolt A, Bagi Z, Koller A (2002) Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia. Am J Pathol 161:145–153
83. Upchurch GR Jr, Welch GN, Loscalzo J (1996) Homocysteine, EDRF, and endothelial function. J Nutr 126(4 Suppl):1290S–1294S
84. Villa P, Bosco P, Ferri R, Perric C, Suriano R, Costantini B, Macri F, Proto C, Cento RM, Lanzone A (2009) Fasting and post-methionine homocysteine levels in Alzheimers disease. Int J Vitam Nutr Res 79:166–172
85. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF, Loscalzo J (2003) Influence of hyperhomocysteinemia on the cellular redox state—impact on homocysteine-induced endothelial dysfunction. Clin Chem Labl Med 41:1455–1461
86. Weiss N, Ide N, Abahji T, Nill L, Keller C, Hoffmann U (2006) Aged garlic extract improves homocysterine-induced endothelial dysfunction in macro- and microcirculation. J Nutr 136(3 Suppl):750S–754S
87. Weiss N, Keller C, Hoffmann U, Loscalzo J (2002) Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 7:227–239
88. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verheugt FW (2002) Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 40:766–772
89. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS (1997) Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542–2544
90. Zhang F, Slungaard A, Vercellotti GM, Iadecola C (1998) Superoxide-dependen cerebrovascular effects of homocysteine. Am J Physiol 274:R1704–R1711
91. Zheng Z, Wang J, Yi L, Yu H, Kong L, Cui W, Chen H, Wang C (2014) Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. Biomed Res Int 2014, 383494. doi:10.1155/2014]383494
92. Zylberstein DE, Bengtsson C, Björkelund C, Landaas S, Sundh V, Thelle D, Lissner L (2004) Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 109:601–606